{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T16:17:08Z","timestamp":1778689028711,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s12072-018-9842-5","type":"journal-article","created":{"date-parts":[[2018,2,8]],"date-time":"2018-02-08T14:41:17Z","timestamp":1518100877000},"page":"17-25","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Autoantibody to apolipoprotein A-1 in hepatitis C virus infection: a role in atherosclerosis?"],"prefix":"10.1007","volume":"12","author":[{"given":"Simon H.","family":"Bridge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Pagano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meleri","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham R.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dermot","family":"Neely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Vuilleumier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret F.","family":"Bassendine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,8]]},"reference":[{"issue":"3","key":"9842_CR1","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jceh.2013.05.004","volume":"3","author":"SK Satapathy","year":"2013","unstructured":"Satapathy SK, Kim YJ, Kataria A, Shifteh A, Bhansali R, Cerulli MA, et al. Higher prevalence and more severe coronary artery disease in hepatitis c virus-infected patients: a case control study. J Clin Exp Hepatol 2013;3(3):186\u2013191.","journal-title":"J Clin Exp Hepatol"},{"issue":"1","key":"9842_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.clinre.2016.09.008","volume":"41","author":"MF Bassendine","year":"2017","unstructured":"Bassendine MF, Nielsen SU, Bridge SH, Felmlee DJ, Sheridan DA, Packard CJ, et al. Hepatitis C virus and atherosclerosis: a legacy after virologic cure? Clin Res Hepatol Gastroenterol 2017;41(1):25\u201330.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"7","key":"9842_CR3","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1089\/aid.2014.0284","volume":"31","author":"KW Chew","year":"2015","unstructured":"Chew KW, Bhattacharya D, McGinnis KA, Horwich TB, Tseng CH, Currier JS, et al. Short communication: coronary heart disease risk by framingham risk score in hepatitis c and hiv\/hepatitis c-coinfected persons. AIDS Res Hum Retrovir 2015;31(7):718\u2013722.","journal-title":"AIDS Res Hum Retrovir"},{"issue":"1","key":"9842_CR4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1365-2893.2005.00655.x","volume":"13","author":"D Siagris","year":"2006","unstructured":"Siagris D, Christofidou M, Theocharis GJ, Pagoni N, Papadimitriou C, Lekkou A, et al. Serum lipid pattern in chronic hepatitis C: histological and virological correlations. J Viral Hepat 2006;13(1):56\u201361.","journal-title":"J Viral Hepat"},{"issue":"1","key":"9842_CR5","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s12016-010-8233-z","volume":"44","author":"P Roux-Lombard","year":"2013","unstructured":"Roux-Lombard P, Pagano S, Montecucco F, Satta N, Vuilleumier N. Auto-antibodies as emergent prognostic markers and possible mediators of ischemic cardiovascular diseases. Clin Rev Allergy Immunol 2013;44(1):84\u201397.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"9","key":"9842_CR6","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1002\/art.27546","volume":"62","author":"N Vuilleumier","year":"2010","unstructured":"Vuilleumier N, Bas S, Pagano S, Montecucco F, Guerne PA, Finckh A, et al. Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2010;62(9):2640\u20132650.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"9842_CR7","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1160\/TH12-10-0714","volume":"109","author":"N Vuilleumier","year":"2013","unstructured":"Vuilleumier N, Montecucco F, Spinella G, Pagano S, Bertolotto M, Pane B, et al. Serum levels of anti-apolipoprotein A-1 auto-antibodies and myeloperoxidase as predictors of major adverse cardiovascular events after carotid endarterectomy. Thromb Haemost 2013;109(4):706\u2013715.","journal-title":"Thromb Haemost"},{"issue":"4","key":"9842_CR8","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/eurheartj\/ehq521","volume":"32","author":"F Montecucco","year":"2011","unstructured":"Montecucco F, Vuilleumier N, Pagano S, Lenglet S, Bertolotto M, Braunersreuther V, et al. Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. Eur Heart J 2011;32(4):412\u2013421.","journal-title":"Eur Heart J"},{"issue":"6","key":"9842_CR9","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1002\/acr.21631","volume":"64","author":"A Finckh","year":"2012","unstructured":"Finckh A, Courvoisier DS, Pagano S, Bas S, Chevallier-Ruggeri P, Hochstrasser D, et al. Evaluation of cardiovascular risk in patients with rheumatoid arthritis: do cardiovascular biomarkers offer added predictive ability over established clinical risk scores? Arthritis Care Res (Hoboken) 2012;64(6):817\u2013825.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"9842_CR10","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.jdiacomp.2016.02.014","volume":"30","author":"D El-Lebedy","year":"2016","unstructured":"El-Lebedy D, Rasheed E, Kafoury M, Abd-El Haleem D, Awadallah E, Ashmawy I. Anti-apolipoprotein A-1 autoantibodies as risk biomarker for cardiovascular diseases in type 2 diabetes mellitus. J Diabetes Complic 2016;30(4):580\u2013585.","journal-title":"J Diabetes Complic"},{"issue":"2","key":"9842_CR11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.dld.2015.10.016","volume":"48","author":"E Vanni","year":"2016","unstructured":"Vanni E, Bugianesi E, Saracco G. Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: myth or reality? Dig Liver Dis 2016;48(2):105\u2013111.","journal-title":"Dig Liver Dis"},{"issue":"15","key":"9842_CR12","doi-asserted-by":"publisher","first-page":"8063","DOI":"10.1128\/JVI.00193-07","volume":"81","author":"MT Catanese","year":"2007","unstructured":"Catanese MT, Graziani R, von Hahn T, Moreau M, Huby T, Paonessa G, et al. High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J Virol 2007;81(15):8063\u20138071.","journal-title":"J Virol"},{"issue":"1","key":"9842_CR13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jhep.2010.06.024","volume":"54","author":"AJ Syder","year":"2011","unstructured":"Syder AJ, Lee H, Zeisel MB, Grove J, Soulier E, Macdonald J, et al. Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J Hepatol 2011;54(1):48\u201355.","journal-title":"J Hepatol"},{"issue":"3","key":"9842_CR14","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1136\/gut.2010.211292","volume":"60","author":"C Mancone","year":"2011","unstructured":"Mancone C, Steindler C, Santangelo L, Simonte G, Vlassi C, Longo MA, et al. Hepatitis C virus production requires apolipoprotein A-I and affects its association with nascent low-density lipoproteins. Gut 2011;60(3):378\u2013386.","journal-title":"Gut"},{"issue":"23","key":"9842_CR15","doi-asserted-by":"publisher","first-page":"9505","DOI":"10.1073\/pnas.1307527110","volume":"110","author":"MT Catanese","year":"2013","unstructured":"Catanese MT, Uryu K, Kopp M, Edwards TJ, Andrus L, Rice WJ, et al. Ultrastructural analysis of hepatitis C virus particles. Proc Natl Acad Sci USA 2013;110(23):9505\u20139510.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"24","key":"9842_CR16","doi-asserted-by":"publisher","first-page":"12020","DOI":"10.1128\/JVI.01569-08","volume":"82","author":"J Grove","year":"2008","unstructured":"Grove J, Nielsen S, Zhong J, Bassendine MF, Drummer HE, Balfe P, et al. Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol 2008;82(24):12020\u201312029.","journal-title":"J Virol"},{"issue":"1","key":"9842_CR17","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1053\/j.gastro.2015.09.014","volume":"150","author":"C Fauvelle","year":"2016","unstructured":"Fauvelle C, Felmlee DJ, Crouchet E, Lee J, Heydmann L, Lefevre M, et al. Apolipoprotein E mediates evasion from hepatitis c virus neutralizing antibodies. Gastroenterology 2016;150(1):206\u2013217.","journal-title":"Gastroenterology"},{"issue":"7","key":"9842_CR18","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1093\/eurheartj\/ehq055","volume":"31","author":"N Vuilleumier","year":"2010","unstructured":"Vuilleumier N, Rossier MF, Pagano S, Python M, Charbonney E, Nkoulou R, et al. Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction. Eur Heart J 2010;31(7):815\u2013823.","journal-title":"Eur Heart J"},{"issue":"5","key":"9842_CR19","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1365-2796.2011.02479.x","volume":"271","author":"PF Keller","year":"2012","unstructured":"Keller PF, Pagano S, Roux-Lombard P, Sigaud P, Rutschmann OT, Mach F, et al. Autoantibodies against apolipoprotein A-1 and phosphorylcholine for diagnosis of non-ST-segment elevation myocardial infarction. J Intern Med 2012;271(5):451\u2013462.","journal-title":"J Intern Med"},{"issue":"7","key":"9842_CR20","doi-asserted-by":"publisher","first-page":"e0132780","DOI":"10.1371\/journal.pone.0132780","volume":"10","author":"S Pagano","year":"2015","unstructured":"Pagano S, Gaertner H, Cerini F, Mannic T, Satta N, Teixeira PC, et al. The human autoantibody response to apolipoprotein A-I is focused on the C-terminal helix: a new rationale for diagnosis and treatment of cardiovascular disease? PLoS One 2015;10(7):e0132780.","journal-title":"PLoS One"},{"issue":"19","key":"9842_CR21","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.4254\/wjh.v7.i19.2214","volume":"7","author":"J Ampuero","year":"2015","unstructured":"Ampuero J, Romero-Gomez M. Assessing cardiovascular risk in hepatitis C: an unmet need. World J Hepatol 2015;7(19):2214\u20132219.","journal-title":"World J Hepatol"},{"issue":"5","key":"9842_CR22","doi-asserted-by":"publisher","first-page":"314","DOI":"10.4330\/wjc.v6.i5.314","volume":"6","author":"N Vuilleumier","year":"2014","unstructured":"Vuilleumier N, Montecucco F, Hartley O. Autoantibodies to apolipoprotein A-1 as a biomarker of cardiovascular autoimmunity. World J Cardiol 2014;6(5):314\u2013326.","journal-title":"World J Cardiol"},{"issue":"3","key":"9842_CR23","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/jre.12014","volume":"48","author":"PA Wick","year":"2013","unstructured":"Wick PA, Mombelli A, Pagano S, Moren X, Giannopoulou C, Mach F, et al. Anti-apolipoprotein A-1 autoantibodies as biomarker for atherosclerosis burden in patients with periodontitis. J Periodontal Res 2013;48(3):350\u2013356.","journal-title":"J Periodontal Res"},{"issue":"4","key":"9842_CR24","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1160\/TH16-03-0248","volume":"116","author":"P Antiochos","year":"2016","unstructured":"Antiochos P, Marques-Vidal P, Virzi J, Pagano S, Satta N, Bastardot F, et al. Association between anti-apolipoprotein A-1 antibodies and cardiovascular disease in the general population. Results from the CoLaus study. Thromb Haemost 2016;116(4):764\u2013771.","journal-title":"Thromb Haemost"},{"key":"9842_CR25","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3389\/fimmu.2017.00437","volume":"8","author":"P Antiochos","year":"2017","unstructured":"Antiochos P, Marques-Vidal P, Virzi J, Pagano S, Satta N, Hartley O, et al. Anti-apolipoprotein A-1 IgG predict all-cause mortality and are associated with Fc receptor-like 3 polymorphisms. Front Immunol 2017;8:437.","journal-title":"Front Immunol"},{"issue":"2","key":"9842_CR26","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1001\/jamainternmed.2013.12505","volume":"174","author":"J McCombs","year":"2014","unstructured":"McCombs J, Matsuda T, Tonnu-Mihara I, Saab S, Hines P, L\u2019Italien G, et al. The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a department of veterans affairs clinical registry. JAMA Intern Med 2014;174(2):204\u2013212.","journal-title":"JAMA Intern Med"},{"issue":"4","key":"9842_CR27","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jhep.2014.11.016","volume":"62","author":"SH Bridge","year":"2015","unstructured":"Bridge SH, Sheridan DA, Felmlee DJ, Crossey MM, Fenwick FI, Lanyon CV, et al. PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: evidence for genotype-specific regulation of lipoprotein metabolism. J Hepatol 2015;62(4):763\u2013770.","journal-title":"J Hepatol"},{"issue":"9","key":"9842_CR28","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/eci.12664","volume":"46","author":"F Carbone","year":"2016","unstructured":"Carbone F, Satta N, Montecucco F, Virzi J, Burger F, Roth A, et al. Anti-ApoA-1 IgG serum levels predict worse poststroke outcomes. Eur J Clin Invest 2016;46(9):805\u2013817.","journal-title":"Eur J Clin Invest"},{"issue":"5","key":"9842_CR29","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/j.1365-2796.2006.01643.x","volume":"259","author":"G Walldius","year":"2006","unstructured":"Walldius G, Jungner I. The apoB\/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy\u2013a review of the evidence. J Intern Med 2006;259(5):493\u2013519.","journal-title":"J Intern Med"},{"issue":"3","key":"9842_CR30","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/hep.27424","volume":"61","author":"EG Meissner","year":"2015","unstructured":"Meissner EG, Lee YJ, Osinusi A, Sims Z, Qin J, Sturdevant D, et al. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. Hepatology 2015;61(3):790\u2013801.","journal-title":"Hepatology"},{"issue":"3","key":"9842_CR31","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/MPG.0b013e3182774cae","volume":"56","author":"JP Molleston","year":"2013","unstructured":"Molleston JP, Mellman W, Narkewicz MR, Balistreri WF, Gonzalez-Peralta RP, Jonas MM, et al. Autoantibodies and autoimmune disease during treatment of children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2013;56(3):304\u2013310.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"8","key":"9842_CR32","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.4254\/wjh.v7.i8.1074","volume":"7","author":"JL Narciso-Schiavon","year":"2015","unstructured":"Narciso-Schiavon JL, Schiavon Lde L. Autoantibodies in chronic hepatitis C: a clinical perspective. World J Hepatol 2015;7(8):1074\u201385.","journal-title":"World J Hepatol"},{"issue":"1","key":"9842_CR33","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1053\/j.gastro.2017.03.006","volume":"153","author":"D Saadoun","year":"2017","unstructured":"Saadoun D, Pol S, Ferfar Y, Alric L, Hezode C, Si Ahmed SN, et al. Efficacy and safety of sofosbuvir plus daclatasvir for treatment of HCV-associated cryoglobulinemia vasculitis. Gastroenterology 2017;153(1):49\u201352.","journal-title":"Gastroenterology"},{"issue":"5","key":"9842_CR34","doi-asserted-by":"publisher","first-page":"e1005610","DOI":"10.1371\/journal.ppat.1005610","volume":"12","author":"S Yamamoto","year":"2016","unstructured":"Yamamoto S, Fukuhara T, Ono C, Uemura K, Kawachi Y, Shiokawa M, et al. Lipoprotein receptors redundantly participate in entry of hepatitis C virus. PLoS Pathog 2016;12(5):e1005610.","journal-title":"PLoS Pathog"},{"issue":"6","key":"9842_CR35","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1046\/j.1365-2893.2002.00369.x","volume":"9","author":"LI Nikolaeva","year":"2002","unstructured":"Nikolaeva LI, Blokhina NP, Tsurikova NN, Voronkova NV, Miminoshvili MI, Braginsky DM, et al. Virus-specific antibody titres in different phases of hepatitis C virus infection. J Viral Hepat. 2002;9(6):429\u201337.","journal-title":"J Viral Hepat"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-018-9842-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-018-9842-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-018-9842-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,8]],"date-time":"2019-02-08T00:53:24Z","timestamp":1549587204000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-018-9842-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["9842"],"URL":"https:\/\/doi.org\/10.1007\/s12072-018-9842-5","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"22 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Ethical approval was obtained from City Road and Hampstead (formerly Moorfields and Whittington) Research Ethics Committee for serial blood sampling of patients with chronic hepatitis C virus infection undergoing antiviral therapy.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Informed consent was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"SHB received financial support from an Anniversary Research Fellowship from Northumbria University. GRF received speaker and consultancy fees from Abbvie, Gilead, BMS (Bristol Myers Squibb), Janssen, Tekmira, Merck and Alcura.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial support"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}